Onabotulinum Toxin A (Botox) for Spasticity in Patients With Acquired Brain Injury


( Last Updated : April 26, 2021)
Project Line:
Health Technology Review
Project Sub Line:
Summary with Critical Appraisal
Project Number:
RC1353-000

Details


Question


  1. What is the clinical effectiveness of onabotulinum toxin A (Botox) for reducing spasticity in patients with acquired brain injury?

  2. What is the cost-effectiveness of onabotulinum toxin A (Botox) for reducing spasticity in patients with acquired brain injury?

  3. What are the evidence-based guidelines regarding the use of onabotulinum toxin A (Botox) for reducing spasticity in patients with acquired brain injury?


Key Message

No relevant literature was identified regarding the clinical effectiveness or cost-effectiveness of onabotulinum toxin A (Botox) for reducing spasticity in patients with traumatic or non-traumaticacquired brain injury. Authors of 1 evidence-based guideline recommend the use of botulinum toxin (subtype and formulation not specified) for the treatment of spasticity associated with traumatic brain injury.